Castlight Health Announces Second Quarter 2015 Results

Aug 5, 2015

 Total Revenue of $18.5 Million, Up 76% Year Over Year

SAN FRANCISCO  August 5, 2015 – Castlight Health, Inc. (NYSE:CSLT), the leader in enterprise healthcare management (EHM), today announced results for its second quarter ended June 30, 2015.

“Castlight continues to gain momentum among large enterprises and we are pleased to now count 10% of the Fortune 500 as our customers. Importantly, we are also seeing our customers expand their relationship with Castlight as we build out our platform,” said Giovanni Colella, M.D., co-founder and chief executive officer of Castlight Health. “This quarter we continued to further our leadership position with the introductions of Castlight Elevate, which enables employees to access behavioral health resources, and Castlight Pulse, our first employer-facing analytics solution.”

Financial Performance for the Three Months Ended June 30, 2015

  • Total revenue for the second quarter of 2015 was $18.5 million, an increase of 76% from the second quarter of 2014. Subscription revenue was $17.3 million, an increase of 80% on a year-over-year basis.
  • Gross margin for the second quarter of 2015 was 55.4%, compared to a gross margin of 29.6% in the second quarter of 2014. Non-GAAP gross margin for the second quarter of 2015 was 58.3% compared to a non-GAAP gross margin of 32.6% in the second quarter of 2014.
  • Operating loss for the second quarter of 2015 was $21.3 million, compared to an operating loss of $21.8 million in the second quarter of 2014. Non-GAAP operating loss for the second quarter of 2015 was $17.6 million, compared to a non-GAAP operating loss of $18.8 million in the second quarter of 2014.
  • Net loss per basic and diluted share was $0.23 in the second quarter of 2015, compared to a net loss per basic and diluted share of $0.24 in the second quarter of 2014. The non-GAAP net loss per basic and diluted share for the second quarter of 2015 was $0.19, compared to a net loss per basic and diluted share of $0.21 in the second quarter of 2014. For both GAAP and non-GAAP purposes, the weighted average basic and diluted share count for the second quarter of 2015 was 93.8 million compared to 89.5 million in the second quarter of 2014.
  • Total cash, cash equivalents and marketable securities were $164.4 million at the end of the second quarter of 2015. Cash used in operations for the second quarter of 2015 was $17.2 million, compared to $19.6 million used in operations in the second quarter of 2014.

A reconciliation of GAAP to non-GAAP results has been provided in this press release in the accompanying tables. An explanation of these measures is also included below under the heading “Non-GAAP Financial Measures”.

Business Outlook

Q3 2015 Guidance: Revenue for the company’s third quarter is expected to be $19.2 million to $19.5 million, representing growth of 57% to 60% on a year-over-year basis. We expect to generate a non-GAAP operating loss in the range of $16.0 million to $17.0 million and a non-GAAP net loss per share of $0.17 to $0.18 based on 95 million weighted average basic and diluted shares outstanding.

Full Year 2015 Guidance: Revenue for the company’s full year 2015 is expected to be in the range of $74.0 million to $77.0 million, an increase of 62% to 69% year-over-year. Non-GAAP operating loss is expected to be in the range of $64.0 million to $67.0 million. Non-GAAP basic and diluted loss per share is expected to be in the range of $0.66 to $0.71 based on 95 million to 97 million weighted average basic and diluted common shares outstanding.

For both the third quarter and the full year 2015, non-GAAP guidance excludes the effects of stock-based compensation expense and capitalization and amortization of internal-use software.

Quarterly Conference Call

Castlight Health will host a conference call to discuss its second quarter 2015 results today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). A live audio webcast of the conference call, together with detailed financial information, can be accessed through the company’s Investor Relations website at In addition, an archive of the webcast can be accessed through the same link. Participants who choose to call in to the conference call can do so by dialing 1-877-201-0168. The conference ID number is 80918941. A replay will be available for one week at 1-855-859-2056, passcode 80918941.

About Castlight Health

Castlight Health, Inc. (NYSE:CSLT) is a leader in Enterprise Healthcare Management. We believe great healthcare builds great business and U.S. enterprises can gain control over the $620 billion spent annually on healthcare, transforming a crippling cost into a strategic business advantage. Recognized as a top 2014 software platform by the HR Technology Conference & Exposition, the Castlight Enterprise Healthcare Cloud enables employers to understand and manage all their healthcare investments while helping employees make the best possible healthcare decisions. Castlight is a great place to work, honored with a Glassdoor Employees’ Choice award and recognized by Rock Health for Diversity in Leadership. For more information visit Follow us on Twitter and LinkedIn and Like us on Facebook. Source: Castlight Health.

Non-GAAP Financial Measures

To supplement Castlight Health’s financial statements presented in accordance with generally accepted accounting principles (GAAP), we also use and provide investors and others with non-GAAP measures of certain components of financial performance, including non-GAAP gross margin (loss), non-GAAP operating expense, non-GAAP operating loss, non-GAAP net loss and non-GAAP net loss per share. These non-GAAP financial measures differ from GAAP financial measures in that they exclude stock-based compensation, warrant expense, capitalization and amortization of internal-use software and the associated tax impact of these items, where applicable.

We believe that these non-GAAP financial measures provide useful supplemental information to investors and others, facilitate the analysis of the company’s core operating results and comparison of operating results across reporting periods, and can help enhance overall understanding of the company’s historical financial performance.

We have provided a reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure, except that we have not reconciled our non-GAAP operating loss and net loss per share guidance for the third quarter of 2015 to comparable GAAP operating loss and net loss per share guidance because we do not provide guidance for stock-based compensation expense and capitalization and amortization of internal-use software, which are reconciling items between GAAP and non-GAAP operating loss. The factors that may impact our future stock-based compensation expense and capitalization and amortization of internal-use software are out of our control and/or cannot be reasonably predicted, and therefore we are unable to provide such guidance without unreasonable effort.

These non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, measures prepared in accordance with GAAP. Further, these non-GAAP measures may differ from the non-GAAP information used by other companies, including peer companies, and therefore comparability may be limited. Castlight Health encourages investors and others to review the company’s financial information in its entirety and not rely on a single financial measure.

Safe Harbor For Forward-Looking Statements

This press release contains forward-looking statements about Castlight Health’s expectations, plans, intentions, and strategies, including, but not limited to, statements regarding Castlight Health’s third quarter and full year projections, our expectations for future performance of our business, market growth and business conditions, future innovation by the company and future developments with respect to the digital healthcare industry. Statements including words such as “anticipate,” “believe,” “estimate,” “will,” “continue,” “expect,” or “future,” and statements in the future tense are forward-looking statements. These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in Castlight Health’s documents filed with or furnished to the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Castlight Health as of the date hereof. Castlight Health assumes no obligation to update these forward-looking statements.

Copyright 2015 Castlight Health, Inc. Castlight Health® is the registered trademark of Castlight Health, Inc. Other company and product names may be trademarks of the respective companies with which they are associated.

(In thousands)
As of
June 30, 2015December 31, 2014
Current assets:
Cash and cash equivalents$31,533$17,425
Marketable securities132,905175,057
Accounts receivable, net11,04811,097
Deferred commissions3,9563,675
Prepaid expenses and other current assets5,9603,476
Total current assets185,402210,730
Property and equipment, net4,5153,630
Marketable securities, noncurrent6,220
Restricted cash, noncurrent1,000
Deferred commissions, noncurrent2,3742,563
Other assets3,692131
Total assets$196,983$223,274
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable$4,180$3,217
Accrued expenses and other current liabilities4,7025,791
Accrued compensation8,73010,455
Deferred revenue24,12520,708
Total current liabilities41,73740,171
Deferred revenue, noncurrent7,6386,652
Other liabilities, noncurrent1,208261
Total liabilities50,58347,084
Commitments and contingencies
Stockholders’ equity146,400176,190
Total liabilities and stockholders’ equity$196,983$223,274
(In thousands, except per share data)
Three Months Ended June 30,Six Months Ended June 30,
Professional services1,2329572,2771,870
Total revenue18,51010,53334,46118,909
Cost of revenue:
Cost of subscription (1)2,9322,9155,4515,627
Cost of professional services (1)5,3224,5029,9758,373
Total cost of revenue8,2547,41715,42614,000
Gross profit10,2563,11619,0354,909
Operating expenses:
Sales and marketing (1)17,64114,94734,10431,507
Research and development (1)7,3915,47613,98511,003
General and administrative (1)6,5174,51911,9808,529
Total operating expenses31,54924,94260,06951,039
Operating loss(21,293)(21,826)(41,034)(46,130)
Other income, net815017973
Net loss$(21,212)$(21,776)$(40,855)$(46,057)
Net loss per share, basic and diluted$(0.23)$(0.24)$(0.44)$(0.86)
Weighted-average shares used to compute basic and diluted net loss per share93,80489,52092,80153,284
(1)Includes stock-based compensation expense as follows:
Three Months Ended June 30,Six Months Ended June 30,
Cost of revenue:
Cost of subscription$67$35$100$39
Cost of professional services450280875420
Sales and marketing2,0741,1523,8252,326
Research and development7304931,363914
General and administrative8969801,9231,794
(In thousands)
Three Months Ended June 30,Six Months Ended June 30,
Operating activities:
Net loss$(21,212)$(21,776)$(40,855)$(46,057)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation4,2172,9408,0865,493
Amortization of deferred commissions8028681,6592,244
Accretion and amortization of marketable securities384373827497
Expense related to warrant702,499
Changes in operating assets and liabilities:
Accounts receivable(560)(4,077)49(5,327)
Deferred commissions(1,113)(1,087)(1,751)(1,369)
Prepaid expenses and other assets(1,848)(596)(1,818)(1,677)
Accounts payable(254)(375)1,258384
Accrued expenses and other liabilities1,2342,173(3,169)(1,203)
Deferred revenue6821,5914,4038,277
Net cash used in operating activities(17,212)(19,574)(30,401)(35,635)
Investing activities:
(Increase) decrease in restricted cash(1,000)101(1,000)101
Investment in related party(3,125)(3,125)
Purchase of property and equipment(806)(311)(1,693)(967)
Purchase of marketable securities(5,924)(126,442)(18,958)(162,175)
Sales of marketable securities5,00013,000
Maturities of marketable securities31,3733,00061,5538,000
Net cash provided by (used in) investing activities20,518(123,652)41,777(142,041)
Financing activities:
Proceeds from the exercise of stock options1,1861062,8261,628
Payments of deferred financing costs(1,679)(94)(3,781)
Net proceeds from initial public offering189,943
Net cash provided by (used in) financing activities1,186(1,573)2,732187,790
Net increase (decrease) in cash and cash equivalents4,492(144,799)14,10810,114
Cash and cash equivalents at beginning of period27,041180,06717,42525,154
Cash and cash equivalents at end of period$31,533$35,268$31,533$35,268
(In thousands, except per share data)
Three Months EndedSix Months Ended
June 30,March 31,June 30,June 30,June 30,
Gross profit:
GAAP gross profit subscription$14,346$12,387$6,661$26,733$11,412
GAAP gross margin subscription83.0%83.1%69.6%83.1%67.0%
Stock-based compensation expense67333510039
Amortization of internal-use software242448
Non-GAAP gross profit subscription$14,437$12,444$6,696$26,881$11,451
Non-GAAP gross margin subscription83.6%83.5%69.9%83.5%67.2%
GAAP gross loss professional services$(4,090)$(3,608)$(3,545)$(7,698)$(6,503)
GAAP gross loss percentage professional services(332)%(345)%(370)%(338)%(348)%
Stock-based compensation expense450425280875420
Non-GAAP gross loss professional services$(3,640)$(3,183)$(3,265)$(6,823)$(6,083)
Non-GAAP gross loss percentage professional services(295)%(305)%(341)%(300)%(325)%
GAAP gross profit$10,256$8,779$3,116$19,035$4,909
GAAP gross margin55.4%55.0%29.6%55.2%26.0%
Impact of non-GAAP adjustments5414823151,023459
Non-GAAP gross profit$10,797$9,261$3,431$20,058$5,368
Non-GAAP gross margin58.3%58.1%32.6%58.2%28.4%
Operating expense:
GAAP sales and marketing$17,641$16,463$14,947$34,104$31,507
Expense related to warrant(70)(2,499)
Stock-based compensation expense(2,074)(1,751)(1,152)(3,825)(2,326)
Non-GAAP sales and marketing$15,567$14,712$13,725$30,279$26,682
GAAP research and development$7,391$6,594$5,476$13,985$11,003
Stock-based compensation expense(730)(633)(493)(1,363)(914)
Capitalization of internal-use software513282795
Non-GAAP research and development$7,174$6,243$4,983$13,417$10,089
GAAP general and administrative$6,517$5,463$4,519$11,980$8,529
Stock-based compensation expense(896)(1,027)(980)(1,923)(1,794)
Non-GAAP general and administrative$5,621$4,436$3,539$10,057$6,735
GAAP operating expense$31,549$28,520$24,942$60,069$51,039
Impact of non-GAAP adjustments(3,187)(3,129)(2,695)(6,316)(7,533)
Non-GAAP operating expense$28,362$25,391$22,247$53,753$43,506
Operating loss:
GAAP operating loss$(21,293)$(19,741)$(21,826)$(41,034)$(46,130)
Impact of non-GAAP adjustments3,7283,6113,0107,3397,992
Non-GAAP operating loss$(17,565)$(16,130)$(18,816)$(33,695)$(38,138)
Net loss and net loss per share:
GAAP net loss$(21,212)$(19,643)$(21,776)$(40,855)$(46,057)
Total pre-tax impact of non-GAAP adjustments3,7283,6113,0107,3397,992
Income tax impact of non-GAAP adjustments
Non-GAAP net loss$(17,484)$(16,032)$(18,766)$(33,516)$(38,065)
Basic and Diluted net loss per share
Shares used in basic and diluted net loss per share computation93,80491,78689,52092,80153,284

Investor Contact:

Charles Butler

[email protected]


Media Contact:

Jim Rivas

[email protected]


Press Information

[email protected]